RDD Pharma Ltd   Report issue

For profit Phase 2 Phase 3
Founded: Ofakim HaDarom Israel (2007)
Status: Acquired by Innovate Biopharmaceuticals (2019)

Organization Overview

First Clinical Trial
2008
NCT00816205
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

RDD Pharma Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

nifedipine (procardia) (4 trials)

Drugs in Phase 2 Trials (3)

mebendazole (vermox) (1 trial)

oxymetazoline (ocuclear) (2 trials)

phenylephrine (Prefrin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fecal Incontinence (Phase 2)

Fissure in Ano (Phase 3)

Pruritus (Phase 2)

Pruritus Ani (Phase 2)

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4